Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04914351Phase 1Completed

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Role: lead

NCT05801237Phase 1Recruiting

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Role: lead

NCT05800249Phase 1Completed

PE0116 Injection in Treatment of Patients With Advanced Solid Tumours

Role: lead

NCT06026501Phase 1Not Yet Recruiting

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Role: collaborator

All 4 trials loaded